CoChat

Antibiotic use and overall survival in lung cancer patients receiving nivolumab.

Do, Tien Phuc, Hegde, Aparna Madhukeshwar, Cherry, Cynthia R., Stroud, Chipman Robert Geoffrey, Sharma, Nitika, Cherukuri, Sulochana Devi, Bowling, Mark, Walker, Paul R. · 2018 · Journal of Clinical Oncology
Cited by 21

The DOI matches its Crossref record.

Abstract

e15109 Background: Recent evidence indicates that the gut microbiome modulates immunotherapy responses in multiple tumor types. Some studies report antibiotics (ATB) may alter the microbiota composition and compromise the therapeutic response of immunotherapy in renal cell carcinoma and melanoma. Methods: We conducted an institutional retrospective review of patients with advanced lung cancer who started nivolumab between April 2015 and May 2017. Follow up cut off was December 31, 2017. Patients who received ATB 30 days before initiating nivolumab to 30 days after the last dose of nivolumab were identified. Kaplan-Meier analysis and Cox proportional hazard model were used to estimate overall survival (OS) and hazard ratios respectively. Results: Among 109 lung cancer patients who received nivolumab in the prespecified time frame, 87(79.8%) received ATB (ATB+), and 22(20.2%) did not (ATB-). Histological types were adenocarcinoma (44/109; 40.4%), squamous cell carcinoma (43/109; 39.5%), small cell (14/109; 12.8%), and other histology (8/109; 7.3%). Of the 87 patients in ATB+ group, 12(13.8%) received penicillins, 11(12.6%) quinolones, 7(8.1%) other antibiotics, and 57(65.5%) multiple antibiotics. The indications for antibiotic use included respiratory (43/87; 49.4%), urinary (9/87; 10.4%), gastrointestinal (4/87; 4.6%), multiple (24/87; 27.6%) and other infections (7/87; 8%). There was no significant difference in the incidence of grade 3-4 adverse events between the two groups (χ2= 0.025, p = 0.88). Survival estimates are as follows- Conclusions: Antibiotic use is prevalent among lung cancer patients treated with immunotherapy. The diminished overall survival in ATB+ group may be due to antibiotic-induced primary resistance to immunotherapy. Prospective trials focused on the minimization of antibiotic use by differentiating true infections from immune related adverse events are necessary. Group 1-year OS (%) Median OS (95% CI) (months) Log rank p = 0.0002 HR (95% CI) p- value ATB- 62.0 17.2 (8.8- 17.2) 0.29 (0.15- 0.58) 0.0004 ATB+ 24.3 5.4 (3.1- 7.7) - -

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2018.36.15_suppl.e15109

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 21

Metadata

Authors
Do, T. P., Hegde, A. M., Cherry, C. R., Stroud, C. R. G., Sharma, N., Cherukuri, S. D., Bowling, M., & Walker, P. R.
Venue
Journal of Clinical Oncology
Published
2018-05-20
Volume
36
Issue
15_suppl
Pages
e15109-e15109
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2891534248
Cited by
21
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibiotic use and overall survival in lung cancer patients receiving nivolumab. https://app.cochat.ai/papers/10.1200/jco.2018.36.15_suppl.e15109
The paper
Do, T. P., Hegde, A. M., Cherry, C. R., Stroud, C. R. G., Sharma, N., Cherukuri, S. D., Bowling, M., & Walker, P. R. (2018). Antibiotic use and overall survival in lung cancer patients receiving nivolumab. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.36.15_suppl.e15109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.